Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KINECT 3: Valbenazine in Tardive Dyskinesia
NCT02274558Phase 3Completed
- Sponsor
- Neurocrine Biosciences
- Start
- Oct 2014
- Primary completion
- Sep 2015
- Modality
- Orthosteric Ligands, Prodrugs/Conditional Activator Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of valbenazine in tardive dyskinesia (TD), sponsored by Neurocrine Biosciences. Started Oct 2014; status: completed.
02
Drugs
valbenazine
03
Conditions
tardive dyskinesia (TD)
Beyond the preview
Go deeper on NCT02274558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02274558.